Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement

Leuk Res. 1987;11(3):265-72. doi: 10.1016/0145-2126(87)90050-6.

Abstract

Two AML patients, whose leukemic clonogenic cells totally reacted to the anti-lactofucopentaose III S4-7 monoclonal antibody (MoAb), underwent autologous bone marrow transplantation, in first complete remission, after in-vitro purging with S4-7 MoAb and complement. After ablative chemotherapy (BAVC regimen) and reinfusion of S4-7 purged cells, regeneration of marrow cells occurred with prompt recovery of granulopoiesis and erythropoiesis. A more delayed platelet recovery was observed. The two patients are in complete remission at 20 and 11 months from ABMT. The results indicate that immunologic purging with S4-7 MoAb is safe and suitable for selected AML patients undergoing ABMT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antigens, Surface / analysis
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow / pathology
  • Bone Marrow Transplantation*
  • Complement System Proteins / immunology*
  • Female
  • Hematopoiesis
  • Humans
  • Leukemia, Myeloid, Acute / immunology
  • Leukemia, Myeloid, Acute / therapy*
  • Lewis X Antigen / immunology*
  • Male
  • Oligosaccharides / immunology*
  • Rabbits
  • Transplantation, Autologous

Substances

  • Antibodies, Monoclonal
  • Antigens, Surface
  • Lewis X Antigen
  • Oligosaccharides
  • Complement System Proteins